Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
117M
-
Number of holders
-
168
-
Total 13F shares, excl. options
-
78.1M
-
Shares change
-
+3.4M
-
Total reported value, excl. options
-
$566M
-
Value change
-
+$18M
-
Put/Call ratio
-
0.06
-
Number of buys
-
92
-
Number of sells
-
-70
-
Price
-
$7.24
Significant Holders of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) as of Q2 2022
193 filings reported holding CHRS - Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share as of Q2 2022.
Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) has 168 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 78.1M shares
of 117M outstanding shares and own 66.73% of the company stock.
Largest 10 shareholders include BlackRock Inc. (12.9M shares), Temasek Holdings (Private) Ltd (7.38M shares), JPMORGAN CHASE & CO (6.49M shares), STATE STREET CORP (6.38M shares), ALLIANCEBERNSTEIN L.P. (5.68M shares), VANGUARD GROUP INC (4.88M shares), PERCEPTIVE ADVISORS LLC (3.65M shares), Kohlberg Kravis Roberts & Co. L.P. (3.04M shares), Aristotle Capital Boston, LLC (2.32M shares), and AMERIPRISE FINANCIAL INC (1.94M shares).
This table shows the top 168 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.